The Medical Letter on Drugs and Therapeutics
Romidepsin (Istodax) for Cutaneous T-Cell Lymphoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved romidepsin (Istodax – Celgene), an IV histone deacetylase (HDAC) inhibitor, for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The most common types of CTCL are mycosis fungoides, a low-grade lymphoma usually confined to the skin, and Sézary syndrome, a more aggressive disease with malignant lymphocytes in the blood. Both can progress to fatal systemic involvement.1 Romidepsin is the second HDAC inhibitor approved for this indication; vorinostat (Zolinza), an oral HDAC inhibitor, was approved earlier.2

STANDARD TREATMENT — Early-stage CTCL can usually be controlled with skin-directed therapies such as topical nitrogen mustard, corticosteroids and retinoids, phototherapy (UVB, PUVA) or radiation. For more advanced stages, FDA-approved systemic therapies include vorinostat, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Romidepsin (Istodax) for Cutaneous T-Cell Lymphoma
Article code: 1339c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian